Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001193125-26-061886

Chief R&D Officer sold 180 shares at $73.00 ($13,140)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2026-02-18 Sale : show line 1 in the form −180 $73.00 $13,140 21,174 D
Open-market sales · 180 sh · avg $73.00 · $13,140
Loading xslF345X05/ownership.xml…